Bob Lutz
Chief Scientific Officer Iksuda Therapeutics
Bob Lutz is a recognized leader in the development of ADCs, with a proven record of advancing breakthrough oncology therapeutics. Since 2015, he has advised biotech and pharma companies worldwide and currently serves as Chief Scientific Officer at Iksuda Therapeutics. Over his 23-year career at ImmunoGen, Inc., he held senior R&D leadership roles, including Vice President of Translational R&D, and played pivotal roles in the development of two FDA-approved ADCs—Kadcyla® and Elahere®.
Seminars
- Positioning protein alkylation as a differentiated and emerging modality within the evolving ADC payload landscape
- Spotlighting the therapeutic potential of ProAlk™ payload through the preclinical profile of IKS073 targeting B7H3 in solid tumors
- Laying out future development journey to progress the first ProAlk™ payload ADC to the clinic
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumor targets, understanding how bioconjugate design contributes and accumulates to performance in the clinic is vital to set up your therapy for success.
Take part in this workshop exploring recent case-study examples to contextualize and understand the performance of different ADC designs to understand what really makes a clinically effective ADC.
Workshop highlights include:
- Accurately correlating and characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Delving into ADC clinical case studies to evaluate differentiated design impact on safety and efficacy profiles to understand what makes a clinically effective ADC
- Finding the right match: Optimizing ADC design to improve payload target pairing
